{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:19:06Z","timestamp":1790191146837,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4631,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1093\/annonc\/mdl484","type":"journal-article","created":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T01:09:17Z","timestamp":1171501757000},"page":"716-721","source":"Crossref","is-referenced-by-count":74,"title":["Pegylated liposomal doxorubicin HCL (PLD; Caelyx\/Doxil\u00ae): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"E.","family":"Andreopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gaiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mirchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1093\/annonc\/mdl484_bb0010","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","volume":"21","author":"Markman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl484_bb0015","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/gyno.2001.6399","article-title":"A phase I\/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer","volume":"83","author":"Bolis","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdl484_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/ijgc-00009577-200505001-00007","article-title":"AGO-OVAR; NCIC CTG; EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer","volume":"15","author":"Pfisterer","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdl484_bb0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1008211909585","article-title":"Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma: a multicenter GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study","volume":"9","author":"Guastalla","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl484_bb0030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/gyno.2001.6364","article-title":"Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer","volume":"83","author":"Gronlund","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdl484_bb0035","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1200\/JCO.1998.16.4.1494","article-title":"Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma","volume":"16","author":"Rose","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdl484_bb0040","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2002.20.5.1238","article-title":"Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer","volume":"20","author":"Dizon","year":"2002","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1093\/annonc\/mdl484_bb0045","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdl484_bb0050","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdl484_bb0055","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdl484_bb0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.8-suppl_2-17","article-title":"Cardiac safety of liposomal anthracyclines","volume":"8","author":"Safra","year":"2003","journal-title":"Oncologist"},{"issue":"2","key":"10.1093\/annonc\/mdl484_bb0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","article-title":"Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages","volume":"82","author":"Rose","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdl484_bb0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/gyno.2000.5980","article-title":"The clinical utility of liposomal doxorubicin in recurrent ovarian cancer","volume":"81","author":"Campos","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdl484_bb0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A","article-title":"Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome","volume":"91","author":"Safra","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdl484_bb0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/j.1552-4604.1996.tb04152.x","article-title":"Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma","volume":"36","author":"Northfelt","year":"1996","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1093\/annonc\/mdl484_bb0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl484_bb0090","article-title":"Caelyx (doxil; liposomal doxorubicin) is tolerated well long-term at high cumulative dose in AIDS-related Kaposi's sarcoma (AIDS-KS) patients\u2014a meta-analysis of 1716 patients","volume":"17","author":"Opravil","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl484_bb0095","article-title":"Decreased risk of cardiotoxicity with long-term use of doxil\/caelyx at high lifetime cumulative doses in patients with AIDS-related Kaposi\/Es sarcoma (KS)","volume":"20","author":"Mustafa","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3 Pt 1","key":"10.1093\/annonc\/mdl484_bb0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5921","article-title":"Phase 2 trial of liposomal doxorubicin (40 mg\/m2) in platinum\/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum","volume":"78","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdl484_bb0105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl484_bb0110","article-title":"Doxil plus cisplatin: combined results of two phase I studies","volume":"17","author":"Klein","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdl484_bb0115","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-04-1240","article-title":"Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer","volume":"11","author":"Mirchandani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdl484_bb0120","first-page":"494","article-title":"Pegylated liposomal doxorubicin (PLD) and carboplatin (C): a phase I study of combination therapy with maintenance PLD","volume":"22","author":"Hamilton","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdl484_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdl484_bb0130","first-page":"458","article-title":"Relationship between pretreatment CA-125 level and risk of relapse in advanced ovarian cancer (AOC) patients in a complete clinical response (CCR) who received \u201cmaintenance therapy\u201d","volume":"24","author":"Liu","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl484_bb0135","article-title":"A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy","volume":"25","author":"Liu","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdl484_bb0140","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2005.04.7373","article-title":"Pretreatment CA-125 and risk of relapse in advanced ovarian cancer","volume":"24","author":"Markman","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3 Suppl 1","key":"10.1093\/annonc\/mdl484_bb0145","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0090-8258(03)00471-2","article-title":"Optimal sequencing in the treatment of recurrent ovarian cancer","volume":"90","author":"Spriggs","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdl484_bb0150","first-page":"44","article-title":"Duration of therapy for ovarian cancer: how long is enough?","volume":"1","author":"Spriggs","year":"2004","journal-title":"Cancer Invest"},{"issue":"13","key":"10.1093\/annonc\/mdl484_bb0155","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1200\/JCO.2003.03.039","article-title":"Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl484_bb0160","first-page":"763a","article-title":"Cardiac safety of pegylated liposomal doxorubicin (PLD) demonstrated by endomyocardial biopsy in patients with advanced malignancies","volume":"22","author":"Gabizon","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdl484_bb0165","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (caelyx\/doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdl484_bb0170","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1002\/1097-0142(19931215)72:12<3671::AID-CNCR2820721219>3.0.CO;2-U","article-title":"Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes","volume":"72","author":"Vaage","year":"1993","journal-title":"Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdl484_bb0175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1093\/annonc\/mdl484_bb0180","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdl484_bb0185","first-page":"223","article-title":"Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet","volume":"7","author":"Gabizon","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1093\/annonc\/mdl484_bb0190","first-page":"5135","article-title":"Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice","volume":"52","author":"Huang","year":"1992","journal-title":"Cancer Res"},{"issue":"13","key":"10.1093\/annonc\/mdl484_bb0195","first-page":"3352","article-title":"Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft","volume":"54","author":"Yuan","year":"1994","journal-title":"Cancer Res"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdl484_bb0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00003495-199700544-00004","article-title":"Opportunities in drug delivery","volume":"54","author":"Allen","year":"1997","journal-title":"Drugs"},{"issue":"1","key":"10.1093\/annonc\/mdl484_bb0205","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2004.03.024","article-title":"Cardiac safety profile of prolonged (>or = 6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies","volume":"94","author":"Uyar","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdl484_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Doxil study 30-49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419378731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419378731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/4\/716\/308858\/mdl484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T18:10:38Z","timestamp":1635790238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419378731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0923753419378731"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl484","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}